SECUENCE LISTING

| ///o7 — Applicant: Steven J. Soldin //207 — Title-of invention: A Novel 8.4 kDa Immunophilin //307 — File-reference: 64688/155 | Does Not Comply Corrected Diskette Needec |
|---|---|
| 2/307 Current application no.: TBA /0/073,334 2/407 Current filing date: TBA 2002-02-13 2/4/7 Current filing date: 09/643,723 2/5/7 Prior application filing date: 08/30/2000 2000-08-3 | 30 . |
| 2/607 Number of SEQ. ID. NOS.: 1 2/707 Software: ASCII (DOS) generic word processing 2/1707 Length: 23 | -)<2107 1 |
| 22137 Organism: mammal | I- The initial letter of the |
| LYS THR ILE THR LEU GLU VAL GLU PRO SER 15 20 ASP THR ILE | anus aid is in upper-case |

The above is the walrd format for a Sequence Listing, Please consult Sequence Rules and the attacked sample Sequence Listing for walrd format

```
<110>
               Smith, John: Smithgene Inc.
               Example of a Sequence Listing
 <120>
               01-00001
 <130>
 <1405
               PCT/EP98/00001
 <1(1>
               1998-12-31
 <150>
              US 08/999,999
              1997-10-15
 <151>
 <160>
 <170>
              Patentin version 2.0
 <210>
              1
              389
 <211>
 <212>
              ANG
              Paramecium sp.
 <213>
<220>
              CDS
<221>
<222>
              (279) . . . (389)
<300>
<301>
              Doc .- Richard .
              Isolation and Characterization of a Gene Encoding a
<302>
              Protease from Paramecium sp.
<303>
              Journal of Genes
<304>
<305>
<306>
             1 - 7
             1988-06-31
<307>
<308>
             123456
<309>
             1988-06-31
<400>
                                                                                        60
agelglagic
             attectgtgt*
                          cctcttctct
                                        ctgggcttct
                                                     caccctgcta
                                                                  atcagatete
                                                                                 E
                                                                                       120
                                                                  ggcaggcagc
                                                     caggcaggca
agggagagtg
             tettgaccèt;
                          cctctgcctt
                                        tgcagottca
                                                                                 ÷ 🛶
                                                                                       180
tgatgtggca
             attigetggea
                          gtgccacagg
                                                     aggettaggg
                                                                  tgggttccgc
                                        cttttcagcc
                                                                                       240
                                                                  cctctcgctc
cgcggcgcgg
             cggcccctct
                          cgcgctcctc
                                        tcgcgcctct
                                                     ctctcgctct
```

....

ゴ

:::::

Appendix 3, page 2

| ttg tet tte as tgg cet ggs ttt tgg ttg file gtt tgg ttg ttg he val cys Leu Phe Cln tgt cec asa gte etc ecc cec tgt cas tes tes tes tes din pro lys val leu pro cys liis tes tes tes tes tes tes din pro Ash Leu Phe Cln 210 | gga (| cctga | tt a | ggtga | gcag | 9899 | aggggg | , ca | gttag | c | atg Het 1 | Val | tca Ser | | ttc Phe S | | 296 |
|--|------------|-------|------------|------------------|---------|---------|------------|-----------------|----------------|-----------------|-----------------|----------------|---------------|----------|------------------------|------------|-----|
| Cys. Pro Lys -Val Leu Pro Cys His Ser Ser -Leu Gln Pro Asn. 1540.7 210> 2 211> 37 212> PRT 212> PRT 213> Paramecium sp. 2400> 2 Het Val Ser Het Phe Ser Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu 1 5 Phe Val Cys Leu Phe Gln Cys Pro Lys Val Leu Pro Cys His Ser Ser 20 Leu Gln Pro Asn Leu 35 210> 2 211> 11 221> PRT 221> PRT 221> PRT 221> PRT 221> Artificial Sequence 220> C220> Designed peptide based on size and polarity to act as a linker between the alpha and beta chains of Protein XYZ. 400> 1 Het Val Asn Leu Glu Pro Met His Thr Glu Ile 1 5 210> 4 210> 4 210> 4 210> 4 | _ | | | Lys | Trp | Pro | Cly | | Cys | ttg Leu | | gtt | tgt | Lcu | | | 344 |
| <pre> <210></pre> | _ | | Lys | -Val | | | _ | His | | | ctg Lcu | cag Gln | Pro | λsn- | ، U احل نــ | : : | 389 |
| <pre> <210 2 211 37</pre> | | • | | • ' • | ٠ | | | | | | : | | | <u> </u> | | | |
| <pre> <(00></pre> | <211 | > | 37 | | | | | | : | r- | No. | · 4 | | | 'x : | ::• | |
| Het Val Ser Het Phe Ser Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu Phe Val Cys Leu Phe Gln Cys Pro Lys Val Leu Pro Cys His Ser Ser Leu Gln Pro Asn Lou 15. Callo | | | | | ium s | ρ. | | | | | * * | | • . • | • | • | | |
| Leu Gln Pro Asn Lou 35. <210> <211> | Het | | | | | Sër | Leu | Ser | Phe | - | 1'rp | Pro | Cly | Phq | | Leu | |
| <pre> <210> <211></pre> | Phe | Val | Cys | | Phe | Cln | Cys | Pro | | Val | l·cu | Pro | Cys | | Ser | Ser - | |
| <pre><211> 11 <212></pre> | Leu | Gln | | | 1.qu | · | | | | | .:· | | | | | | |
| <pre><211> 11 <212></pre> | <210> | • | Ċ | | / | · | | | | | ÷ | | | | •• | | |
| <220> <223> Designed peptide based on size and polarity to act as a linker between the alpha and beta chains of Protein XYZ. <400> 3 Met Val Asn Leu Glu Pro Met His Thr Glu Ile 1 5 10 <210> 4 <400> 4 | <211><211> | • | 1 1 FR1 | | | | | | | ÷ | | | | | | | |
| <pre></pre> | <213> | • | VL | . 1116 | 191 20 | equenc | c | | | / | | | | | | | |
| Met Val Asn Leu Glu Pro Met His Thr Glu 11e 1 5 10 <210> 4 <400> 4 | | | Des | signed aker l | j pepu | ide b | ased o | on si: a and | ze and beta | l pola chair | rity is of | to ac Prote | t as in XY | a Z . | - | | |
| <400> 4 | Het | | - | Leu | | Pro | мет | His | Thr | - | He | | | | | | |
| | <400> | | | | · .• | | | | | | | | | | ŧ | | |

[Annex VIII follows]

r

table. The numeric identifier shall be used only in the "Sequence Listing." The order and presentation of the items of information in the "Sequence Listing" shall conform to the arrangement given below. Each item of information shall begin on a new line and shall begin with the numeric identifier enclosed in angle brackets as shown. The submission of those items of information designated with an "M" is mandatory. The submission of those items of information designated with an "O" is optional. Numeric identifiers <110> through <170> shall only be set forth at the beginning of the "Sequence Listing." The following table illustrates the numeric identifiers.

| Numeric Identifier | Definition | Comments and Format | Mandatory (M) or . Optional (O) |
|-----------------------|---------------------------------|--|--|
| <110> | Λpplicant | Preferably max. of 10 names; one name per line; preferable format: Surname, Other, Names and/or Initials | M |
| <120> | Title of Invention | | м |
| <130> | File Reference | Personal file reference | M when filed prior to assignment of appl. number |
| <140> | Current Applica- tion Number | Specify as: US 07/999,999 or PCT/US96/99999 | M, if available |
| <141> | Current Filing Date | Specify as: yyyy-mm-dd | M, if available |
| <150> | Prior Application Number | Specify as: US 07/999,999 or PCT/US96/99999 | M, if applicable include priority documents under 35 USC 119 and 120 |
| <151> | Prior Application Filing Date | Specify as: yyyy-mm-dd | M, if applicable |
| <160> | Number of SEQ ID NOs | Count includes total number of SEQ ID NOs | М |
| <170> | Software | Name of software used to create the Sequence Listing | 0 = |
| <210> | SEQ ID NO: #: | Response shall be an integer representing the SEQ ID NO shown | м |
| <211> | Length | Respond with an integer expressing the number of bases or amino acid residues | M |

7:2:1

Whether presented sequence moleculc is DNA, RNA, or PRT (protein). If a nucleotide sequence contains both DNA and RNA fragments, the type shall be "DNA." In addition, the combined DNA/ RNA molecule shall be further described in the <220> to <223> (cature section.

<213>

Organism.

Scientific name, i.e. Genus/species, Unknown or Artificial Sequence. In addition, the "Unknown" or "Artificial Sequence" organisms shall be further described in the <220> to <223> feature section.

<220>

Feature

Leave blank after <220>. <221-223> provide for a description of points of biological significance in the sequence.

M, under the following conditions: if "n,"
"Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGAN-ISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.

<221>

Name/Key

Provide appropriate identifier for feature, pre-ferably from WIPO Standard ST.25 (1998), Appendix 2, Tables 5 and 6

M, under the following conditions:= if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence

<222>

Location

Specify location within sequence; where appropriate state number of first and last bases/amino acids

M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified

1/29/99 L 53 PKS

Other Infor-

mation

<223>

Other relevant

four lines maximum

information;

bas as used in a s ence

M, under the following conditions: if "n," "Xaa," or a modified or un-

| • | | | a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if a molecule is com- | | | | |
|---------|---------------------------------|---|--|--------------|--|--|--|
| | | | bined DNA/RNA================================== | | | | |
| <300> : | Publication Information | Leave blank [:] after <300> /- | ************************************** | | | | |
| <301> | Authors | Preferably max of ten named authors of publi- | <i>≯</i> ₩ 0 | | | | |
| | ; ; | cation; specify one name per line; preferable format: | | | | | |
| | ; | Surname, Other Names and/or Initials | * | n + villa; b | | | |
| <302> | Tit <u>l</u> e | | * o | | | | |
| <303> | ; Journal | : | 0 | | | | |
| <304> | Volume | | 0 | | | | |
| <305> | Issue | ; | 0 | | | | |
| <306> | Pages | | 0. | • | | | |
| <307> | Date | Journal date on which data published; specify as yyyy-mm-dd, MMM-yyyy or Season-yyyy | h O | | | | |
| <300> | Database Accession Number | Accession number assigned by data-base including database name | O == | | | | |
| <309> | Database Entry Date | Date of entry in database; specify as yyyy-mm-dd or MMM-yyyy | 0 | | | | |
| <310> | Patent Document Number | Document number; for patent-type citations only. Specify as, for example, US 07/999,999 | 0 | | | | |

Document filing <311> Patent Filin date, for patent-Date type citations only; specify as yyyy-mm-dd <312> Publication Date Document publication date, for patent-type citations only; specify as yyyy-mm-dd <313> Relevant FROM (position) TO 0 Residues (position) <400> Sequence SEQ ID NO should .:M follow the numeric identifier and should appear on the line preceding the actual sequence

- 5. Section 1.024 is revised to read as follows:
- 1.024 Form and format for nucleotide and/or amino acid sequence submissions in computer readable form.
- (a) The computer readable form required by 1.821(e) shall meet the following specifications:
- (1) The computer readable form shall contain a single "Sequence Listing" as either a diskette, series of diskettes, or other permissible media outlined in paragraph (c) of this section.
- (2) The "Sequence Listing" in paragraph (a) (1) of this section shall be submitted in American Standard Code for Information Interchange (ASCII) text. No other formats shall be allowed.
- (3) The computer readable form may be created by any means, such as word processors, nucleotide/amino acid sequence editors or other custom computer programs; however, it shall conform to all specifications detailed in this section.
- (4) File compression is acceptable when using diskette media, so long as the compressed file is in a self-extracting format that will decompress on one of the systems described in paragraph (b) of this section.
- (5) Page numbering shall not appear within the computer readable form version of the "Sequence Listing" (ile.
- (6) All computer readable (orms shall have a label permanently as(ixed thereto on which has been hand-printed or typed: the name of the applicant, the title of the invention, the date on which the data were recorded on the computer readable (orm, the operating system used, a reference number, and an application serial number and (iling date, if known.
- (b) Computer readable form submissions must meet these format requirements:
- (1) Computer: IBM PC/XT/AT. or compatibles, or Apple Macintosh;
- (2) Operating System: MS-DOS, Unix or Macintosh;

#:#:t